RG 6036
Alternative Names: RG-6036Latest Information Update: 25 Nov 2022
At a glance
- Originator Roche
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 25 Nov 2022 Chugai Pharmaceutical in-licenses RG 6036 from Roche prior to November 2022
- 24 Oct 2022 Phase-I clinical trials in Solid tumours in Japan (PO) (Chugai Pharmaceutical pipeline, November 2022)